Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

869
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
869
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

452
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
452
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

586
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
586
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

1000
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1000
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

602
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
602
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
884

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A history of research into the physiology of bile, from Hippocrates to molecular medicine.

Clinical liver disease·2022
Same author

Of the Necessity of Rigor and Critical Sense in Historical Research.

Journal of anesthesia history·2019
Same author

Is Frederic Chopin's Death Elucidated?

The American journal of medicine·2018
Same author

Cystic fibrosis liver disease in adults: Limits of noninvasive tests of fibrosis.

Hepatology (Baltimore, Md.)·2017
Same author

Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2017
Same author

A microbial peptide to rescue severe and fulminant Wilson disease?

Clinics and research in hepatology and gastroenterology·2016

Related Experiment Video

Updated: Mar 12, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

55.1K

Obeticholic acid in primary biliary cholangitis.

Serge Erlinger1

  • 1University of Paris 7, 75013 Paris, France.

Clinics and Research in Hepatology and Gastroenterology
|November 10, 2016
PubMed
Summary

Obeticholic acid significantly lowered liver enzymes in primary biliary cholangitis patients. However, increased pruritus and adverse effects warrant further investigation into its safety and efficacy.

Area of Science:

  • Hepatology
  • Pharmacology
  • Clinical Trials

Background:

  • Primary biliary cholangitis (PBC) is a chronic liver disease.
  • Ursodeoxycholic acid is a standard treatment for PBC.
  • Novel therapeutic agents are needed for PBC management.

Purpose of the Study:

  • To evaluate the efficacy and safety of obeticholic acid in patients with primary biliary cholangitis.
  • To assess obeticholic acid as an add-on therapy to ursodeoxycholic acid or as monotherapy.

Main Methods:

  • Double-blind, randomized, placebo-controlled study.
  • 217 patients with primary biliary cholangitis were enrolled.
  • Patients received obeticholic acid with ursodeoxycholic acid or as monotherapy, or placebo.

Related Experiment Videos

Last Updated: Mar 12, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

55.1K

Main Results:

  • Obeticholic acid significantly decreased serum alkaline phosphatase and bilirubin compared to placebo.
  • A decrease in serum bile acid concentration was observed.
  • Pruritus and serious adverse effects were more frequent in the obeticholic acid group.

Conclusions:

  • Obeticholic acid demonstrates potential in improving biochemical markers for PBC.
  • Further studies are required to confirm clinical efficacy and long-term safety.
  • Careful patient selection and monitoring may be necessary for obeticholic acid treatment.